Levaquin Leva-Pak en es it fr

Levaquin Leva-Pak Brand names, Levaquin Leva-Pak Analogs

Levaquin Leva-Pak Brand Names Mixture

  • No information avaliable

Levaquin Leva-Pak Chemical_Formula

C36H42F2N6O9

Levaquin Leva-Pak RX_link

http://www.rxlist.com/cgi/generic2/quixin.htm

Levaquin Leva-Pak fda sheet

Levaquin_Leva-Pak FDA

Levaquin Leva-Pak msds (material safety sheet)

Levaquin Leva-Pak Synthesis Reference

Mitscher, Lester A. et al.; J.Med.Chem.; 30; 12; 2283-2286(1987)

Levaquin Leva-Pak Molecular Weight

740.751 g/mol

Levaquin Leva-Pak Melting Point

No information avaliable

Levaquin Leva-Pak H2O Solubility

Insoluble

Levaquin Leva-Pak State

Solid

Levaquin Leva-Pak LogP

1.268

Levaquin Leva-Pak Dosage Forms

Tablet; Liquid; Solution

Levaquin Leva-Pak Indication

For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.

Levaquin Leva-Pak Pharmacology

Levofloxacin, a fluoroquinolone antiinfective, is the optically active L-isomer of ofloxacin. Levofloxacin is used to treat bacterial conjunctivitis, sinusitis, chronic bronchitis, community-acquired pneumonia and pneumonia caused by penicillin-resistant strains of Streptococcus pneumoniae, skin and skin structure infections, complicated urinary tract infections and acute pyelonephritis.

Levaquin Leva-Pak Absorption

Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.

Levaquin Leva-Pak side effects and Toxicity

Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face

Levaquin Leva-Pak Patient Information

PATIENT INFORMATION

While taking ofloxacin patient should be advised to:

— to drink fluids liberally;

— that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx®, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;

— that ofloxacin can be taken without regard to meals;

— that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;

— to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;

— that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction

— to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;

— that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;

— that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.

Levaquin Leva-Pak Organisms Affected

Enteric bacteria and other eubacteria